July 2025 in “Clinical Medicine” Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
20 citations
,
January 2017 in “Experimental Dermatology” Igf1r helps regulate hair growth cycles.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
1 citations
,
June 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
1 citations
,
June 2023 in “American Journal of Clinical Dermatology” Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
Yifa Compound Prescription helps hair follicles grow better in lab conditions.
December 2025 in “Педиатрическая фармакология” Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
November 2025 in “Journal of Investigative Dermatology”
October 2024 in “Canadian Journal of Health Technologies” Olumiant should be covered for severe alopecia areata if certain conditions are met.
2 citations
,
February 2023 in “Anais Brasileiros de Dermatologia”
5 citations
,
August 2018 in “PubMed” An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.
31 citations
,
January 2016 in “Skin Appendage Disorders” Frontal fibrosing alopecia and vitiligo might be linked, not just coincidental.
7 citations
,
July 2024 in “Dermatology Practical & Conceptual” SII is a useful and affordable tool to assess and monitor alopecia areata.
1 citations
,
June 2022 in “International Journal of Dermatology” FFA in men shows unique features and treatment results vary widely.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
11 citations
,
May 2022 in “Journal of immunology research” Breast implants are linked to autoimmune symptoms, with over half of patients feeling better after removal, but the exact cause is unclear and may involve bacterial biofilm.
September 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
44 citations
,
October 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
159 citations
,
August 2010 in “British journal of dermatology/British journal of dermatology, Supplement” Hydroxychloroquine effectively reduces symptoms of frontal fibrosing alopecia, especially in the first 6 months.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Early treatment and multidisciplinary care are key to managing Frontal Fibrosing Alopecia and preventing further hair loss.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
March 2025 in “NATIONS UNIVERSITY INTERNATIONAL JOURNAL OF MULTI-DISCIPLINARY STUDIES” Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.
14 citations
,
March 2023 in “Scientific Reports” Oxidative stress, not insulin resistance, is significantly related to free androgen index in PCOS.
January 2020 in “Clinical Case Reports and Reviews” Lupus and frontal fibrosing alopecia may share a common cause.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
29 citations
,
November 2015 in “Acta Biomaterialia” Infrared light can trigger drug release from gold nanoparticle carriers in hair follicles.